和誉-B:与艾力斯就ABSK043与枸橼酸戈来雷塞片联合用于治疗NSCLC达成合作协议

格隆汇
24 Mar

格隆汇3月24日丨和誉-B(02256.HK)发布公告,公司的附属公司上海和誉生物医药科技有限公司(“和誉医药”)今日宣布,已与艾力斯(688578.SH)达成合作协议,探索将和誉医药在研的口服PD-L1 抑制剂ABSK043与艾力斯的KRAS-G12C抑制剂枸橼酸戈来雷塞片联合用于治疗 KRAS-G12C突变的非小细胞肺癌患者。【免责声明】本文仅代表作者本人观点,与和讯网无关。和讯网站对文中陈述...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10